Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01612390|
Recruitment Status : Unknown
Verified June 2012 by Rasha Mohammed Mohammed Badawi, Ain Shams University.
Recruitment status was: Not yet recruiting
First Posted : June 5, 2012
Last Update Posted : June 5, 2012
|Condition or disease|
|Postpartum Hemorrhage Prevention by Using Oxytocin Verses Misoprostol|
|Study Type :||Observational|
|Estimated Enrollment :||180 participants|
|Observational Model:||Case Control|
|Official Title:||Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor|
|Study Start Date :||August 2012|
|Estimated Primary Completion Date :||August 2013|
|Estimated Study Completion Date :||December 2013|
receive 400 Mg sublingual misoprostol.
receive 600 Mg sublingual misoprostol.
receive 5IU of intravenous oxytocin.
- reduce blood loss during third and fourth stages of labor. [ Time Frame: 1 year ]reduce blood loss during third and fourth stages of labor by using misopristol is better than using oxytocin
- the duration of the third stage of labor ,need for oxytocics ,blood transfusion and any adverse effects of the drugs [ Time Frame: 1 year ]the duration of the third stage of labor ,needed for oxytocics ,blood transfusion and any adverse effects of the drug will be reduced with mesopristol
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01612390
|Contact: Rasha mohamed, M.B;B.CHemail@example.com|
|Cairo, Egypt, 44511|
|Principal Investigator:||RBadawi mohamed, M.B;B.CH||Ain Shams University|